BioAtla, Inc. (BCAB): restructuring charge — BioAtla initiates strategic review, cuts 70% workforce; CFO replaced; cash ~$7.1M

BioAtla, Inc.

Workforce reduced ~70%; severance costs estimated $0.5-0.6M; committed Feb 24, 2026.
CFO Richard Waldron departs March 2; succeeded by Chief Accounting Officer Chris Vasquez.
Formal strategic review launched to monetize assets; Tungsten Advisors engaged as advisor.
Preliminary cash and cash equivalents $7.1M as of Dec 31, 2025; no PPA amounts outstanding.
Nasdaq delisting review ongoing; $40M SPV transaction with Inversagen AI not yet closed.

item 2.02 item 7.01 item 2.05 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

BioAtla, Inc. announced a restructuring with charges of between $0.5 and $0.6 million affecting the Company (approximately 70%).

Type: restructuring
Charge: between $0.5 and $0.6 million
Affected area: the Company
Headcount: approximately 70%

Exact text from the filing

formal process to explore and evaluate strategic options to maximize shareholder value. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs. The Company expects to pay for the majority of these costs in the first quarter of 2026. The estimates of the

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001539497-26-000812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.